178 related articles for article (PubMed ID: 37234150)
21. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.
Veelken H; Vik Dannheim S; Schulte Moenting J; Martens UM; Finke J; Schmitt-Graeff A
Ann Oncol; 2007 May; 18(5):931-9. PubMed ID: 17395602
[TBL] [Abstract][Full Text] [Related]
23. Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Hematol Oncol; 2017 Dec; 35(4):440-446. PubMed ID: 27238634
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
26. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
27. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
28. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
29. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.
Plonquet A; Haioun C; Jais JP; Debard AL; Salles G; Bene MC; Feugier P; Rabian C; Casasnovas O; Labalette M; Kuhlein E; Farcet JP; Emile JF; Gisselbrecht C; Delfau-Larue MH;
Ann Oncol; 2007 Jul; 18(7):1209-15. PubMed ID: 17496307
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
Yu T; Xu-Monette ZY; Lagoo A; Shuai W; Wang B; Neff J; Carrillo LF; Carlsen ED; Pina-Oviedo S; Young KH
Front Immunol; 2024; 15():1335689. PubMed ID: 38348048
[TBL] [Abstract][Full Text] [Related]
31. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
[TBL] [Abstract][Full Text] [Related]
32. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
[TBL] [Abstract][Full Text] [Related]
34. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
Song JY; Nwangwu M; He TF; Zhang W; Meawad H; Bedell V; Murata-Collins J; Skrabek P; Nasr MR; Scott D; Godfrey J; Lee P; Chan WC; Weisenburger DD; Perry AM; Herrera AF
Haematologica; 2023 Aug; 108(8):2167-2177. PubMed ID: 36632739
[TBL] [Abstract][Full Text] [Related]
35. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
36. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
37. High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma.
Chang C; Wu SY; Kang YW; Lin KP; Chen TY; Medeiros LJ; Chang KC
Am J Clin Pathol; 2015 Dec; 144(6):935-44. PubMed ID: 26573001
[TBL] [Abstract][Full Text] [Related]
38. Peripheral immune cell profiling of double-hit lymphoma by mass cytometry.
Lei T; Wu G; Xu Y; Zhuang W; Lu J; Han S; Zhuang Y; Dong X; Yang H
BMC Cancer; 2023 Feb; 23(1):184. PubMed ID: 36823603
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
